Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Stenocare - Update: Rekordsalg i 2023 og break-even i 2024

Planlagt Fastgjort Låst Flyttet Debatforum
1 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #1

    STENOCARE A/S
    NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
    TICKER: STENO

    This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on Nov 6, 2023.

    For 4 years, STENOCARE has been working hard to reach and exceed the sales volumes of 2018 and 2019, its first two years of successful operation.

    This announcement is made ahead of the Q3-22 report in order to share with the market the recent positive development in sales and the related updated guidance for 2023 and 2024. For more details, see graph in attachment to this press release.

    Læs resten af meddelelsen i vedhæftning.

    Stenocare har en betalt digital IR-aftale med Proinvestor.com

    116569_2023_11_06_STENOCARE_Updated_guidance_for_2023_and_2024.pdf
    116569_Graph___Sales_overview_2018_to_2024.jpg

    1 Reply Last reply
    2
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #2

      STENOCARE A/S
      NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
      TICKER: STENO

      STENOCARE: One-off return of products from Norway

      This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation.

      The information was provided by the contact person below for publication on Nov 6, 2023.

      Return of products: On 28 October 2022, STENOCARE was able to proudly announce its access to the Norwegian market, making STENOCARE the first and only supplier of full spectrum oil based medical cannabis products in Norway. The initial projections for number of patients were based on historic pain treatment data in Norwegian pain centres. Then, during Q4, 2022, STENOCARE shipped products to its new local partner, Apotek 1, the leading distributor and pharmacy chain in Norway to supply these patients with their full spectrum medical cannabis oil products. However, it turned out that the management of the pain centres (hospitals) decided to hold back the budget for treatment with all cannabis-based products - which slowed down sales run rate and resulted in products expiring. Due to this situation in Norway, products worth DKK 2,1m have now been returned to STENOCARE

      Læs hele meddelelsen i vedhæftning:

      Stenocare har en betalt digital IR-aftale med Proinvestor.com

      116570_2023_11_06_STENOCARE_financial_update___One_off_return_of_products_in_Q3.pdf

      1 Reply Last reply
      2

      Hello! It looks like you're interested in this conversation, but you don't have an account yet.

      Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

      With your input, this post could be even better 💗

      Tilmeld Log ind

      • Log ind

      • Har du ikke en konto? Tilmeld

      • Login or register to search.
      • First post
        Last post
      0
      • Debatforum
      • Seneste
      • Populære
      • Bruger